How cancer and immune cell metabolism shape blood cancers and treatment response
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
This project sees if the metabolism of cancer and immune cells in the bone marrow affects treatment outcomes for adults with blood cancers such as AML, MDS, ALL, and myelofibrosis.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 350 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Basel) |
| Trial ID | NCT07189117 on ClinicalTrials.gov |
What this trial studies
This observational study will perform detailed metabolic profiling of malignant cells, immune cells, and extracellular metabolites from bone marrow samples across disease stages and treatment time points. Participants include adults with hematologic malignancies (AML, MDS, ALL, primary or post‑ET/PV myelofibrosis) and healthy donors, with samples analyzed for cellular respiration, metabolite levels, and immune cell function. The goal is to map metabolic interactions that may drive therapy resistance and relapse, particularly in the context of allogeneic hematopoietic stem cell transplantation. Findings could point to metabolic pathways that are actionable targets for new treatments or for tailoring existing therapies to individual patients.
Who should consider this trial
Good fit: Adults (over 18) who can give informed consent and have a diagnosis of AML, MDS, ALL, primary myelofibrosis, or post‑ET/PV myelofibrosis are the intended participants.
Not a fit: Pregnant or lactating people, those unable to consent, patients with other active malignancies within the past three years, and healthy donors should not expect direct therapeutic benefit from participation.
Why it matters
Potential benefit: If successful, the work could reveal metabolic targets or biomarkers that help reduce relapse and guide more personalized treatment strategies for patients with blood cancers.
How similar studies have performed: Preclinical and early clinical work suggests metabolic pathways can influence cancer and immune responses, but comprehensive human bone marrow metabolic profiling in these blood cancers remains relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \> 18 years, * signed written informed consent * For participants with hematological cancers: diagnosis of MDS, AML, ALL, PMF or post-ET/PV MF Exclusion Criteria: * pregnant or lactating women, * inability to give consent, * active malignant disease (other than MDS, AML, ALL, PMF or post-ET/PV MF in the last 3 - years prior to study inclusion). * For healthy donors: previous or current hematological disease, previous or current other malignant disease,
Where this trial is running
Basel
- University Hospital Basel — Basel, Switzerland (Recruiting)
Study contacts
- Principal investigator: Johannes Tossounidis, MD — University Hospital of Basel
- Study coordinator: Petya Apostolova, Prof. Dr.
- Email: petya.apostolova@unibas.ch
- Phone: +41 61 328 48 40
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.